Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia
Open Access
- 10 April 2013
- journal article
- clinical trial
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 54 (6), 880-886
- https://doi.org/10.2967/jnumed.112.114785
Abstract
11C-Pittsburgh compound-B (11C-PiB) is the benchmark radiotracer for imaging of β-amyloid (Aβ) plaque in Alzheimer disease (AD). 18F-labeled Aβ tracers subsequently developed for clinical use show higher nonspecific white matter binding and, in some cases, lower cortical binding in AD that could lead to less accurate interpretation of scans. We compared the cortical and white matter binding of a new 18F-labeled Aβ tracer, 18F-AZD4694 (recently renamed NAV4694), with 11C-PiB in the same subjects. Methods: Forty-five participants underwent PET imaging with 11C-PiB and 18F-AZD4694 (25 healthy elderly controls [HCs], 10 subjects with mild cognitive impairment, 7 subjects with probable AD, and 3 subjects with probable frontotemporal dementia). Images were coregistered so that region-of-interest placement was identical on both scans, and standardized uptake value ratios (SUVRs) using the cerebellar cortex as a reference region were calculated between 40 and 70 min after injection for both tracers. Results: 18F-AZD4694 showed reversible binding kinetics similar to 11C-PiB, reaching an apparent steady state at 50 min after injection. Both radiotracers showed a similar dynamic range of neocortical SUVR (1.1–3.3 and 1.0–3.2 SUVR for 11C-PiB and 18F-AZD4694, respectively) and identical low nonspecific white matter binding, with frontal cortex–to–white matter ratios of 0.7 ± 0.2 and 1.3 ± 0.2 for both radiotracers in HCs and AD subjects, respectively. There was an excellent linear correlation between 11C-PiB and 18F-AZD4694 neocortical SUVR (slope of 0.95, r = 0.99, P < 0.0001). Conclusion: 18F-AZD4694 displays imaging characteristics nearly identical to those of 11C-PiB. The low white matter and high cortical binding in AD indicate that this tracer is well suited to both clinical and research use.This publication has 35 references indexed in Scilit:
- A European multicentre PET study of fibrillar amyloid in Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer diseaseAnnals of Neurology, 2011
- Assessment of β-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11–Labeled Pittsburgh Compound BArchives of Neurology, 2008
- The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other DementiasMolecular Neurobiology, 2008
- Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's diseaseBrain, 2008
- Imaging β-amyloid burden in aging and dementiaNeurology, 2007
- 11 C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degenerationNeurology, 2007
- Molecular Imaging With Pittsburgh Compound B Confirmed at AutopsyArchives of Neurology, 2007
- Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humansAnnals of Neurology, 2006
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004